Fresenius Medical Care (FMS) Tops Q1 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Fresenius Renal Therapies Announces the Introduction of Next Generation Sentinel Technology to Support Fluid Management Challenges in the End Stage Renal Disease Community
May 2, 2016 9:51 AM EDTWALTHAM, Mass.--(BUSINESS WIRE)-- Fresenius Renal Therapies, a division of Fresenius Medical Care North America (FMCNA), the leading provider of products and services for the chronic kidney disease patient, announced today the introduction of its latest technological enhancement in the Crit-Line® technology product line, the CLiC device.
The CLiC device non-invasively measures hematocrit, oxygen saturation and percent change in intravascular blood volume during a patients hemodialysis (HD) treatment. As an integrated feature in the 2008T hemodialysis machine, the organizations flagship HD delivery system, the healthcare professional has immediate, real-time access to a patients hematocrit, percent... More
